CD8A and neoplasm: As a novel intracellular checkpoint in CD8+ T cells within the tumour microenvironment, RIG-I represents a promising therapeutic target that can enhance the function of CD8+ T cells, particularly in the treatment of solid tumours that are resistant to PD-1 antibodies.